???pagination.result.count???
The plant-derived alkaloid aloperine prevents ischemia/reperfusion injury-induced sudden cardiac death. , Hu Z., FASEB J. July 1, 2023; 37 (7): e22999.
Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer. , Levin M ., Cell. April 15, 2021;
Toward a Structural View of hERG Activation by the Small-Molecule Activator ICA-105574. , Zangerl-Plessl EM., J Chem Inf Model. January 27, 2020; 60 (1): 360-371.
Stoichiometry of altered hERG1 channel gating by small molecule activators. , Wu W., J Gen Physiol. April 1, 2014; 143 (4): 499-512.
The Eag domain regulates the voltage-dependent inactivation of rat Eag1 K+ channels. , Lin TF., PLoS One. January 1, 2014; 9 (10): e110423.
VEGFA-dependent and -independent pathways synergise to drive Scl expression and initiate programming of the blood stem cell lineage in Xenopus. , Ciau-Uitz A ., Development. June 1, 2013; 140 (12): 2632-42.
Blocking of the human ether-à- go-go-related gene channel by imatinib mesylate. , Dong Q., Biol Pharm Bull. January 1, 2013; 36 (2): 268-75.
PIKfyve sensitivity of hERG channels. , Pakladok T., Cell Physiol Biochem. January 1, 2013; 31 (6): 785-94.
A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins. , Peigneur S., FASEB J. December 1, 2012; 26 (12): 5141-51.
Kcnh1 voltage-gated potassium channels are essential for early zebrafish development. , Stengel R., J Biol Chem. October 12, 2012; 287 (42): 35565-35575.
Marine algal toxin azaspiracid is an open-state blocker of hERG potassium channels. , Twiner MJ., Chem Res Toxicol. September 17, 2012; 25 (9): 1975-84.
Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule. , Garg V., J Gen Physiol. September 1, 2012; 140 (3): 307-24.
Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A. , Kulzer M., Biochem Biophys Res Commun. July 27, 2012; 424 (2): 315-20.
18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels. , Du YM., Acta Pharmacol Sin. June 1, 2012; 33 (6): 752-60.
A molecular switch driving inactivation in the cardiac K+ channel HERG. , Köpfer DA., PLoS One. January 1, 2012; 7 (7): e41023.
Molecular determinants for activation of human ether-à- go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide. , Garg V., Mol Pharmacol. October 1, 2011; 80 (4): 630-7.
Effects of the histamine H(1) receptor antagonist hydroxyzine on hERG K(+) channels and cardiac action potential duration. , Lee BH., Acta Pharmacol Sin. September 1, 2011; 32 (9): 1128-37.
A bifunctional sea anemone peptide with Kunitz type protease and potassium channel inhibiting properties. , Peigneur S., Biochem Pharmacol. July 1, 2011; 82 (1): 81-90.
hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds. , Hishigaki H., Database (Oxford). May 17, 2011; 2011 bar017.
Recombinant expression of the toxic peptide ErgTx1 and role of Met35 on its stability and function. , Jimenez-Vargas JM., Peptides. March 1, 2011; 32 (3): 560-7.
A potent potassium channel blocker from Mesobuthus eupeus scorpion venom. , Gao B., Biochimie. December 1, 2010; 92 (12): 1847-53.
Aconitine blocks HERG and Kv1.5 potassium channels. , Li Y., J Ethnopharmacol. August 19, 2010; 131 (1): 187-95.
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. , Obers S., Naunyn Schmiedebergs Arch Pharmacol. May 1, 2010; 381 (5): 385-400.
Tel1/ ETV6 specifies blood stem cells through the agency of VEGF signaling. , Ciau-Uitz A ., Dev Cell. April 20, 2010; 18 (4): 569-78.
Block of the human ether-a- go-go-related gene ( hERG) K+ channel by the antidepressant desipramine. , Hong HK., Biochem Biophys Res Commun. April 9, 2010; 394 (3): 536-41.
Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652. , Xing J., Eur J Pharmacol. March 25, 2010; 630 (1-3): 1-9.
H(1) antihistamine drug promethazine directly blocks hERG K(+) channel. , Jo SH., Pharmacol Res. November 1, 2009; 60 (5): 429-37.
The evolutionarily conserved residue A653 plays a key role in HERG channel closing. , Stepanovic SZ., J Physiol. June 1, 2009; 587 (Pt 11): 2555-66.
Block of HERG k channel by classic histamine h(1) receptor antagonist chlorpheniramine. , Hong HK., Korean J Physiol Pharmacol. June 1, 2009; 13 (3): 215-20.
Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. , Fanoe S., Br J Clin Pharmacol. February 1, 2009; 67 (2): 172-9.
Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. , Scherer D., Br J Pharmacol. January 1, 2009; 156 (2): 226-36.
Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. , Scherer D., Naunyn Schmiedebergs Arch Pharmacol. July 1, 2008; 378 (1): 73-83.
Probing the binding sites and mechanisms of action of two human ether-a- go-go-related gene channel activators, 1,3- bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243). , Xu X., Mol Pharmacol. June 1, 2008; 73 (6): 1709-21.
Gambierol, a toxin produced by the dinoflagellate Gambierdiscus toxicus, is a potent blocker of voltage-gated potassium channels. , Cuypers E., Toxicon. May 1, 2008; 51 (6): 974-83.
An extracellular Cu2+ binding site in the voltage sensor of BK and Shaker potassium channels. , Ma Z., J Gen Physiol. May 1, 2008; 131 (5): 483-502.
Modulation of voltage-gated Na+ and K+ channels by pumiliotoxin 251D: a "joint venture" alkaloid from arthropods and amphibians. , Vandendriessche T., Toxicon. March 1, 2008; 51 (3): 334-44.
Protriptyline block of the human ether-à- go-go-related gene ( HERG) K+ channel. , Jo SH., Life Sci. January 30, 2008; 82 (5-6): 331-40.
Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide. , Lin C., Cardiology. January 1, 2008; 110 (3): 209-16.
The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. , Lin C., Cardiology. January 1, 2008; 110 (3): 145-52.
Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. , Scholz EP., Naunyn Schmiedebergs Arch Pharmacol. December 1, 2007; 376 (4): 275-84.
Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. , Duan JJ., Acta Pharmacol Sin. July 1, 2007; 28 (7): 959-67.
Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling. , Tseng GN., Biophys J. May 15, 2007; 92 (10): 3524-40.
Modulation of ERG channels by XE991. , Elmedyb P., Basic Clin Pharmacol Toxicol. May 1, 2007; 100 (5): 316-22.
The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. , Lin C., Cardiology. January 1, 2007; 108 (1): 18-27.
The effects of quinidine and its chiral isolates on erg-1sm potassium current and correlation with gastrointestinal augmentation. , Cvetanovic I., Am J Ther. January 1, 2007; 14 (3): 269-76.
In vitro modulation of HERG channels by organochlorine solvent trichlormethane as potential explanation for proarrhythmic effects of chloroform. , Scholz EP., Toxicol Lett. August 20, 2006; 165 (2): 156-66.
[Electrophysiological characterization of long QT syndrome associated mutations V630A and N633S]. , She HR., Zhonghua Xin Xue Guan Bing Za Zhi. June 1, 2006; 34 (6): 523-7.
Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels. , Kiesecker C., Naunyn Schmiedebergs Arch Pharmacol. June 1, 2006; 373 (3): 212-20.
Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels. , Clarke CE., J Physiol. June 1, 2006; 573 (Pt 2): 291-304.
Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. , Lee SY., Br J Pharmacol. June 1, 2006; 148 (4): 499-509.